QRxPharma (ASX: QRX) announced that a number of patients have been treated in the first of several clinical studies to be conducted as part of the Phase III development program for its lead product candidate Q8003IR, an immediate release dual opioid pain therapy. The initial clinical trial is a double-blind, placebo-controlled study designed to compare the efficacy and safety of four different dosage strengths of Q8003IR vs. [click link for full article]

More: continued here

This entry was posted on Sunday, December 2nd, 2007 at 5:12 am and is filed under Pain / Anesthetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.